Renalytix plc (RNLXY) shareholders
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Ownership
Who owns Renalytix's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Icahn School Of Medicine At Mount Sinai (“ismms”) | 35,653,477 | 10.68% | 13D (active) amendment | Nov 1, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mount Sinai Hospitals Group, Inc. 10% owner | Nov 1, 2024 | Other | +13,366,750 | $0.12 | $1.60M | 32,683,998 |
| School Of Medicine At Mount Sinai Icahn 10% owner | Apr 24, 2024 | Other | +9,360,374 | $0.25 | $2.34M | 19,317,248 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Renalytix's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,987 shares on Sep 4, 2026 over the last 90 days.
See a number that looks wrong?